Non-invasive interventions for improving well-being and quality of life in patients with lung cancer

2003 ◽  
Author(s):  
I Solà ◽  
E Thompson ◽  
M Subirana ◽  
C López ◽  
A Pascual
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Well Being ◽  
Non Invasive

Non-invasive interventions for improving well-being and quality of life in patients with lung cancer

2004 ◽  
Author(s):  
Ivan Solà ◽  
Elinor M Thompson ◽  
Mireia Subirana Casacuberta ◽  
Consol Lopez ◽  
Antonio Pascual
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Well Being ◽  
Non Invasive

Improvement in symptoms and quality of life (QoL) for patients (p) with non-small cell lung cancer (NSCLC) treated with erloninib: TargeT study

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 18140-18140
Author(s):  
V. Alberola ◽  
O. Gallego ◽  
G. López-Vivanco ◽  
C. Mesía ◽  
J. Oramas ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Cancer Therapy ◽  
Functional Assessment ◽  
Objective Response ◽  
Well Being ◽  
End Point ◽  
Trial Outcome Index ◽  
Outcome Index

18140 Background: Erlotinib is an EGFR TKI that is effective in the treatment of advanced NSCLC, in terms of longer survival, better quality of life and delayed symptom progression.We present here the outcome of a group of p from the TargeT study, whose QoL was assessed by the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire and the Lung Cancer Subscale (LCS). Methods: TargeT study was a multicenter, single-arm phase II study evaluating efficacy, safety, and tolerability of erlotinib (150 m/day) in p with stage IIIB or IV NSCLC, in 1st, 2nd and 3rd line treatment. Primary end-point was time to progression. QoL was a secondary end point as assessed monthly by the Functional Assessment of Cancer Therapy-Lung questionnaire (FACT- L) and its Lung Cancer Subscale. Physical and functional aspects of the QoL were measured by the Trial Outcome Index (TOI), which is the sum of the physical well being, functional well-being and LCS scores from the FACT-L questionnaire. Results: Data from 91 pts were available. QoL analysis showed that 53% of the p (95% IC 37–58%) had improvement in FACT-L or TOI. Similarly, 45% (95% IC35–56%) of improved their symptoms from baseline. Improvement was observed for each individual LCS item and specifically in the pulmonary items. In symptomatic p, shortened of breath was 17,6% at baseline vs 2.2% after treatment (p<0.001) and cough was 24.7% vs 8.8 % (p<0.001) after treatment. Those improvements in symptoms were rapid and, 73% of the patients who improved showed that recovery in the first cycle of treatment. In terms of association between efficacy of erlotinib and QoL, there is a statistically significative relationship between objective response and improvement in TOI or FACT-L (p<0.02). Conclusions: This QoL analysis confirms that erlotinib improves both symptoms and functional aspect of patients with NSCLC. The improvement in QoL is related with objective response. No significant financial relationships to disclose.

scholarly journals Risk Factors and Quality of Life of Lung Cancer Survivors in Lahore, Pakistan

2021 ◽  
pp. 68-71
Author(s):  
Rehan Ahmad Khan Sherwani ◽  
Sajjad Ali Gill ◽  
Saba Younus ◽  
Sana Saeed ◽  
Nadia Saeed ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Risk Factors ◽  
Lung Cancer ◽  
Family History ◽  
Cancer Patients ◽  
Environmental History ◽  
Well Being ◽  
Lung Cancer Patients ◽  
History Of

Introduction: The objectives of this study is to determine the risk factors of lung cancer were patients and investigate the quality of life of lung cancer survivors. The occupational, smoking, personal, environmental and family history of the survivors are investigated. The well-being of the survivors with physical and social norms not were also studied. Methods: Risk factors and quality of life from a sample of 50 lung cancer patients investigated through a self-administered questionnaire after getting consent from the hospital management and the patients. All the analysis has been done in SPSS 21. Results: Most of the lung cancer patients were male smokers with a strong history of smoking, and more than half of the respondents inhaled while smoking cigarettes. The significant risk factors among non-smokers are occupational history, personal history, environmental history, and family history. The impact of environmental history with smoking history is observed in lung cancer patients. The physical well-being of the patients is considerably affected by the disease and the pain in their daily activities. Conclusion: Smoking remained the leading risk factor of lung cancer patients followed by radon. However, family history is found statistically significant in the prevalence of lung cancer. Authorities should draw and implement some guiding rules to control smoking, radon, and air pollution, particularly in residential areas.

Quality of life in poor prognosis patients with locally advanced non-small cell lung cancer (LA-NSCLC) undergoing a phase II study of concurrent cetuximab and definitive thoracic radiotherapy followed by docetaxel and cetuximab.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e17559-e17559
Author(s):  
Lora Thompson ◽  
Martine Extermann ◽  
Thomas J. Dilling ◽  
Jongphil Kim ◽  
Binglin Yue ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Activities Of Daily Living ◽  
Daily Living ◽  
Locally Advanced ◽  
Well Being ◽  
Thoracic Radiotherapy ◽  
Significant Difference ◽  
Specific Symptoms

e17559 Background: A single institution prospective clinical trial was conducted to examine the safety and efficacy of concurrent cetuximab and definitive thoracic radiotherapy followed by docetaxel plus cetuximab. Quality of life (QOL) was assessed as a secondary endpoint. Survival and toxicity data are presented separately. Methods: Eligible pts with unresectable stage IIA or IIIB LA-NSCLC, who also had ECOG PS 2 OR weight loss ≥5% in 3 months OR age >70, completed QOL measures at baseline, after concurrent cetuximab/radiotherapy (recovery), and after docetaxol/cetuximab (consolidation). Scores were calculated for Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Fatigue Symptom Inventory (FSI) worst fatigue, FSI fatigue interference, and Functional Assessment of Cancer Therapy – Lung Trial Outcome Index (FACT-L TOI). FACT-L TOI assessed physical (e.g., nausea) and functional (e.g., difficulty sleeping) well-being as well as lung cancer specific symptoms (e.g., shortness of breath, cough). Descriptive and t-test results are presented. Results: Pts (N = 27) were primarily male (67%) and non-Hispanic Caucasian (96%) with mean age of 73 years. High attrition between recovery (N = 22) and consolidation (N = 10) occurred. Compared to baseline, pts reported higher levels of worst fatigue (p < .03) and fatigue interference (p = .01) at recovery. There was a decline in IADLs (p = .01) but no significant difference in ADLs or FACT-L TOI. Further examination of FACT subscales revealed declines in physical (p < .0001) and functional (p = .02) well-being but improvement in lung cancer specific symptoms (p < .0001). A similar pattern is found for comparisons between baseline and consolidation (ps < .05). There were no significant differences between recovery and consolidation. Conclusions: Although pts experienced declines in QOL across most domains after concurrent cetuximab and radiotherapy, there was improvement in lung cancer specific symptoms. Pts were also able to maintain their ability to perform ADLs. High attrition after recovery is a notable limitation.

scholarly journals QUALITY OF LIFE IN OLDER ADULTS RECEIVING IMMUNE CHECKPOINT INHIBITOR THERAPY

2019 ◽  
Vol 3 (Supplement_1) ◽  
pp. S313-S313
Author(s):  
Aasha I Hoogland ◽  
Sarah L Eisel ◽  
Nathaly E Irizarry-Arroyo ◽  
Brian James ◽  
Jori Mansfield ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Older Adults ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Older Patients ◽  
Well Being ◽  
Over Time

Abstract Immune checkpoint inhibitors (ICIs) have generated significant excitement for their ability to extend survival in patients with lung, head and neck, and other cancers. In older adults with cancer, emerging research suggests that ICIs improve overall and progression-free survival, but few studies have reported on quality of life (QOL). The goal of this study was to examine changes in QOL over time in older (65+ years) vs. younger (&lt;65 years) lung and head and neck cancer patients. Eligible participants scheduled to begin ICI for lung or head and neck cancer completed the Functional Assessment of Cancer Therapy General (FACT-G) every 2-4 weeks until disease progression. Controlling for cancer site, age group differences in QOL over time were evaluated using linear mixed models. A total of 80 lung cancer (mean age=66.5, 55% female, 55% aged 65+) and 55 head and neck cancer patients (mean age=61.5, 15% female, 45% aged 65+) provided consent. At baseline, patients with head and neck cancer reported significantly lower overall QOL, physical well-being, and emotional well-being compared to patients with lung cancer (ps&lt;.0001). Older patients had marginally higher baseline emotional well-being than younger patients (p=.07). Across groups, there were increases in social well-being (p=.04) and a trend toward decreasing physical well-being (p=.10) over time. Patients with head and neck cancer reported lower emotional well-being over time than patients with lung cancer (p&lt;.01). There were no age differences in QOL over time. Larger longitudinal studies are needed to better understand QOL in older patients receiving ICIs.

Sign in / Sign up

Export Citation Format

Share Document